You are here

Selective DAT Inhbitor for the Treatment of Obesity

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43DK081293-01
Agency Tracking Number: DK081293
Amount: $212,981.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: PHS2007-2
Solicitation Year: 2008
Award Year: 2008
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
United States
DUNS: 182472162
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (513) 475-6618
Business Contact
Phone: (513) 475-6618
Research Institution

DESCRIPTION (provided by applicant): The purpose of the present SBIR Phase 1 feasibility study is to assess the efficacy of our selective dopamine transport (DAT) inhibitor, PD2007, for the treatment of obesity. The non-selective DAT inhibitor, d-amphetami
ne, is a potent anti-obesity treatment in humans. However, d- amphetamine, is not clinically approved for the treatment of obesity due primarily to its significant abuse and addiction potential. Preliminary Studies indicate that our benztropine analog, PD2
007, is as effective as d-amphetamine at decreasing food intake. Preliminary Studies also indicate that PD2007 demonstrates no abuse potential in preclinical studies. That is, PD2007 does not support self- administered in monkeys. The long term goal of the
proposed studies is to develop a safe and effective anti-obesity treatment with little or no abuse potential. Extensive research suggests that DAT inhibition is the anti-obesity mechanism of action of d- amphetamine. Benztropine is a selective hig
h affinity DAT inhibitor that is safe and effective and in clinical use for over 30 years. Benztropine demonstrates no significant abuse potential and is a non- Scheduled drug. Unfortunately, benztropine is a potent anticholinergic which precludes it use a
s an anti-obesity treatment. Extensive lead optimization studies have identified the benzotropine analog, PD2007, as a selective DAT inhibitor with no anticholinergic properties and with no abuse potential in preclinical studies. The purpose of the
proposed Specific Aims is to assess PD2007's effect on food intake, body weight and body fat in a well established preclinical model of obesity (high fat diet-induced obesity), as well as, to determine PD2007's effect on obesity related co-morbidities. Sp
ecific Aim 1: Determine the effect of PD2007 on food intake, body weight, energy expenditure, circadian activity levels and regional body fat/lean body mass in high-fat diet- induce obesity rats and standard lab chow diet rats. Specific Aim 2: Dete
rmine the effects of PD2007 on obesity-related co-morbidities in Specific Aim 1 animals (triglycerides, cholesterol, leptin, insulin and inflammatory cytokines levels, as well as, glucose tolerance and insulin-sensitivity). PUBLIC HEALTH RELEVANCE: In the
present application, we propose preclinical studies to assess whether our proprietary compound, PD2007-a selective inhibitor of the dopamine transporter, is an effective treatment for obesity. These preclinical studies will assess the effect of varying do
ses of PD2007 on obesity induced by a high fat diet in rats as well as in rats fed a standard lab chow diet. Rats, like humans, when fed a diet rich in fats increase their food intake and become obese. The ability of PD2007 to decrease food intake, decreas
e body fat and to reverse obesity related co-morbidities such as insulin resistance and glucose intolerance will be determined in both groups of animals.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government